David and Scott formed Gliknik based upon their wish to use their medical training to ease human suffering through development of better drugs for people living with cancer and autoimmune diseases.
David and Scott Strome first met each other through their children.
For several years, Gliknik CEO David Block headed the DuPont Merck commercial team that brought the HIV drug Sustiva® to commercialization.
Scott Strome is the co-inventor of antibody therapeutics to PD-L1, which may be particularly beneficial in helping to treat a range of cancers.